Menu Search
Equities

Cogent Biosciences Inc

COGT:NSQ

Cogent Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.90
  • Today's Change0.35 / 3.32%
  • Shares traded1.10m
  • 1 Year change+1.87%
  • Beta1.7292
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Cogent Biosciences Inc have a median target of 16.50, with a high estimate of 22.00 and a low estimate of 10.00. The median estimate represents a 51.38% increase from the last price of 10.90.
High101.8%22.00
Med51.4%16.50
Low-8.3%10.00

Earnings history & estimates in USD

On Aug 06, 2024, Cogent Biosciences Inc reported 2nd quarter 2024 losses of -0.590 per share. This result was in line with the consensus of the 10 analysts following the company and was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate-0.12%
Cogent Biosciences Inc reported annual 2023 losses of -2.42 per share on Feb 26, 2024.
Average growth rate-57.33%
More ▼

Revenue history & estimates in USD

Unum Therapeutics Inc. did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Unum Therapeutics Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate-41.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.